These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 19769440)

  • 1. Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients?
    Kingwell E; Tremlett H
    Expert Rev Neurother; 2009 Sep; 9(9):1263-5. PubMed ID: 19769440
    [No Abstract]   [Full Text] [Related]  

  • 2. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.
    Garg N; Weinstock-Guttman B; Bhasi K; Locke J; Ramanathan M
    Mult Scler; 2007 Aug; 13(7):895-9. PubMed ID: 17468449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of tobacco smoking on clinical effectiveness of immunomodulatory treatment in multiple sclerosis patients].
    Jernas Ł; Piorunek T; Tokarz E; Wygladalska-Jernas H; Kozubski W; Michalak S
    Przegl Lek; 2012; 69(10):750-2. PubMed ID: 23421025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon after 10 years in patients with multiple sclerosis.
    Pozzilli C; Prosperini L; Sbardella E; Paolillo A
    Neurol Sci; 2006 Sep; 27 Suppl 5():S369-72. PubMed ID: 16998723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
    Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Wiertlevski S; Defer G; Gout O; Berthier F; Danzon A
    Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gap between effect of drugs and effectiveness of treatments.
    Sorensen PS
    J Neurol Sci; 2007 Aug; 259(1-2):128-32. PubMed ID: 17362994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 10. Suicide attempts in multiple sclerosis.
    Stenager EN; Jensen B; Stenager M; Stenager K; Stenager E
    Mult Scler; 2011 Oct; 17(10):1265-8. PubMed ID: 21511689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based medicine and clinical trials.
    Coyle PK
    Neurology; 2007 Jun; 68(24 Suppl 4):S3-7. PubMed ID: 17562847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta for multiple sclerosis: Long-term benefits?
    Rudick RA; Cutter G
    Ann Neurol; 2007 Apr; 61(4):283-5. PubMed ID: 17444503
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study.
    Weber-Schoendorfer C; Schaefer C
    Mult Scler; 2009 Sep; 15(9):1037-42. PubMed ID: 19692433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
    Azoulay D; Mausner-Fainberg K; Urshansky N; Fahoum F; Karni A
    J Neuroimmunol; 2009 Jun; 211(1-2):114-9. PubMed ID: 19419774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies to interferon.
    Noronha A
    Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Still no evidence on the efficacy of immunomodulatory therapy in reducing functional impairment in multiple sclerosis].
    Vermeulen M
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):850-1. PubMed ID: 17472114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
    Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A
    Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
    McNaughton H; Kayes N; McPherson K
    N Z Med J; 2006 Apr; 119(1232):U1939. PubMed ID: 16633398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC; Hartung HP
    Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.